Effects of Sacubitril/Valsartan According to Polypharmacy Status in PARAGON-HF
European Journal of Heart Failure · 2024
DOI: 10.1002/ejhf.3223 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Shingo Matsumoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Valsartan, Aminobutyrates, Biphenyl Compounds, Drug Combinations. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Aims
Patients with heart failure (HF) and preserved ejection fraction (HFpEF) have a particularly high prevalence of comorbidities, often necessitating treatment with many medications. The aim of this study was to evaluate the association between polypharmacy status and outcomes in PARAGON-HF. Methods and results In this post hoc analysis, baseline medication status was available in 4793 of 4796 patients included in the primary analysis of PARAGON-HF. The effects of sacubitril/valsartan, compared with valsartan, were assessed according to the number of medications at baseline: 683 non-polypharmacy (<5 medications); 2750 polypharmacy (5–9 medications), and 1360 hyper-polypharmacy (≥10 medications). The primary outcome was total HF hospitalizations and cardiovascular deaths. Patients with hyper-polypharmacy were older, had more severe limitations due to HF (worse New York Heart Association class and Kansas City Cardiomyopathy Questionnaire scores), and had greater comorbidity. The non-adjusted risk of the primary outcome was significantly higher in patients taking more medications, and similar trends were seen for HF hospitalization and cardiovascular and all-cause death. The effect of sacubitril/valsartan versus valsartan on the primary outcome from the lowest to highest polypharmacy category was (as a rate ratio): 1.19 (0.76–1.85), 0.94 (0.77–1.15), and 0.77 (0.61–0.96) (pinteraction = 0.16). Treatment-related adverse events were more common in patients in the higher polypharmacy categories but not more common with sacubitril/valsartan, versus valsartan, in any polypharmacy category.
Conclusions
Polypharmacy is very common in patients with HFpEF, and those with polypharmacy have worse clinical status and a higher rate of non-fatal and fatal outcomes. The benefit of sacubitril/valsartan was not diminished in patients taking a larger number of medications at baseline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- Institut de Cardiologie de Montréal, Université de Montréal, Montreal, Quebec, Canada.
- Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis, MN, USA.
- Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA.
Zitieren
APA
Matsumoto, S., Yang, M., Shen, L., Henderson, A., Claggett, B. L., Desai, A. S., Lefkowitz, M., Rouleau, J. L., Vardeny, O., Zile, M. R., Jhund, P. S., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2024). Effects of Sacubitril/Valsartan According to Polypharmacy Status in PARAGON-HF. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3223
Vancouver
Matsumoto S, Yang M, Shen L, Henderson A, Claggett BL, Desai AS, et al. Effects of Sacubitril/Valsartan According to Polypharmacy Status in PARAGON-HF. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3223
BibTeX
@article{Matsumoto2024,
author = {Matsumoto, Shingo and Yang, Mingming and Shen, Li and Henderson, Alasdair and Claggett, Brian L and Desai, Akshay S and Lefkowitz, Martin and Rouleau, Jean L and Vardeny, Orly and Zile, Michael R and Jhund, Pardeep S and Vaduganathan, Muthiah and Solomon, Scott D and McMurray, John J V},
title = {Effects of Sacubitril/Valsartan According to Polypharmacy Status in PARAGON-HF},
journal = {European Journal of Heart Failure},
year = {2024},
doi = {10.1002/ejhf.3223}
}
EUVIMED